This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

This study has been completed.
Information provided by:
Affiris AG Identifier:
First received: September 2, 2009
Last updated: October 18, 2010
Last verified: October 2010
This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.

Condition Intervention Phase
Alzheimer's Disease Biological: AFFITOPE AD02 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002

Resource links provided by NLM:

Further study details as provided by Affiris AG:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: July 2010 ]
    • Withdrawal criteria (continuation decision) Number of patients who withdraw due to AEs Reason for withdrawal
    • Adverse events (AEs)
    • Serious adverse events (SAEs)
    • Physical and neurological examination
    • Concomitant medication
    • Vital signs (blood pressure, heart rate, respiratory rate, body temperature)
    • Body mass (weight and height)
    • MRI of brain
    • ECG
    • Laboratory assessment (haematology, biochemistry, coagulation, serology and urinalysis)

Secondary Outcome Measures:
  • Immunological and clinical activity [ Time Frame: July 2010 ]

    Immunological parameters:

    - Assessment of the immune response triggered by the vaccine (titre of IgG antibodies specific for the immunizing peptide, N-terminal part of Aβ, (irrelevant peptide serves as specificity control), Aβ itself and KLH as assessed by ELlSA as well as the results of the biacore affinity measurements towards the immunizing peptide and Aβ)

    Clinical efficacy variables:

    • Cognitive and functional tests, behavioural scales
    • Measurement of quality of life in patients with Alzheimer's disease
    • Investigator's global evaluation scale

Enrollment: 20
Study Start Date: October 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AFFITOPE AD02 Biological: AFFITOPE AD02
s.c. injection


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participation in AFF002 and AFF004

Exclusion Criteria:

  • Presence or history of allergy to components of the vaccine, if considered relevant by the investigator
  • Contraindication for MRI imaging
  • History and/or presence of autoimmune disease, if considered relevant by the investigator
  • Active infectious disease (e.g., Hepatitis B, C)
  • Presence and/or history of Immunodeficiency (e.g., HIV)
  • Significant systemic illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01093664

Ordination Schmitz
Vienna, Austria, 1010
Sponsors and Collaborators
Affiris AG
Principal Investigator: Margot Schmitz, Univ. Doz. Ordination Schmitz
  More Information

Responsible Party: Achim Schneeberger, MD, AFFiRiS AG Identifier: NCT01093664     History of Changes
Other Study ID Numbers: AFF004A
Study First Received: September 2, 2009
Last Updated: October 18, 2010

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Immunologic Factors
Physiological Effects of Drugs processed this record on September 20, 2017